The Analyst Landscape: 5 Takes On Omnicell
The Analyst Landscape: 5 Takes On Omnicell
分析師視角：對omnicell的五種看法
Analysts' ratings for Omnicell (NASDAQ:OMCL) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
過去一個季度，5位分析師對Omnicell（納斯達克代碼：OMCL）的評級從看好到看淡不一。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了分析師們最近的評級，揭示了過去30天內情緒的變化並將其與前幾個月進行了比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.6, along with a high estimate of $44.00 and a low estimate of $30.00. Marking an increase of 25.33%, the current average surpasses the previous average price target of $30.00.
奧姆尼塞爾公司爲醫療保健提供自動化和業務分析軟件。它幫助客戶定義和提供成本效益的藥物管理，旨在使藥劑師和護士將重點放在患者護理而不是行政工作上，並在所有護理環境中提供改進的臨床、運營和財務結果。奧姆尼塞爾在美國產生絕大部分收入。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
The perception of Omnicell by financial experts is analyzed through recent analyst...
營業收入下降：在過去的3...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。